Insilico Medicine (HKG:3696) said Tuesday it has initiated a phase 3 clinical trial of rentosertib in China, according to a Wednesday filing with the Hong Kong bourse.
Shares of the biotechnology company rose 3% in recent trade.
The trial is designed to evaluate the efficacy and safety of the drug in treating idiopathic pulmonary fibrosis, a lung disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.